Rebecca L. Eccles

Rebecca L. Eccles

Auto-generated profile, based on publicly available information

Rebecca L. Eccles

Cancer Grand Challenges, Cancer Research UK, London, UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2019 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
MSMarc P. Stemmler
Marc P. Stemmler
RERebecca L. Eccles
Rebecca L. Eccles
SBSimone Brabletz
Simone Brabletz
TBThomas Brabletz
Thomas Brabletz

7 October 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
RERebecca L. Eccles
Rebecca L. Eccles
MCMaciej T. Czajkowski
Maciej T. Czajkowski
CBCarolin Barth
Carolin Barth
PMPaul Markus Müller
Paul Markus Müller
EMErik McShane
Erik McShane
OROliver Rocks
Oliver Rocks
Protein kinase A is a key mediator of cAMP signalling downstream of G-protein-coupled receptors, a signalling pathway conserved in all eukaryotes. cAMP binding to the regulatory subunits (PKAR) relieves their inhibition of the catalytic subunits (PKAC). Here we report that ARHGAP36 combines two distinct inhibitory mechanisms to antagonise PKA signalling. First, it blocks PKAC activity via a pseudosubstrate motif, akin to the mechanism employed by the protein kinase inhibitor proteins. Second, it targets PKAC for rapid ubiquitin-mediated lysosomal degradation, a pathway usually reserved for transmembrane receptors. ARHGAP36 thus dampens the sensitivity of cells to cAMP. We show that PKA inhibition by ARHGAP36 promotes derepression of the Hedgehog signalling pathway, thereby providing a simple rationale for the upregulation of ARHGAP36 in medulloblastoma. Our work reveals a new layer of PKA regulation that may play an important role in development and disease.

1 August 2011 in Traffic
Verified
Journal Article
Open access
PDF file
CTChristopher Thorne
Christopher Thorne
RERebecca L. Eccles
Rebecca L. Eccles
JCJudy M Coulson
Judy M Coulson
SUSylvie Urbé
Sylvie Urbé
MCMichael J. Clague
Michael J. Clague
Ubiquitin‐specific protease 33 (USP33) is a deubiquitinase that has been associated with a variety of physiological events. Here, we show the existence of multiple USP33 splice variants and characterize the sub‐cellular localization of endogenous USP33 as well as GFP‐USP33 isoforms 1–3. The localization of USP33 is broadly confined to the secretory pathway, with all variants localizing to endoplasmic reticulum‐associated structures. In addition, GFP‐USP33 variant 3 shows a marked accumulation at the Golgi apparatus. Several deubiquitinases have large insertions within their otherwise highly conserved catalytic domains, the function of which is poorly characterized. Analysis of USP33 reveals a role for two distinct inserts within the catalytic domain. One is required for association with the endoplasmic reticulum, whilst the second is required for membrane association, but can be alternatively spliced (variant 3) to excise eight amino acids, which otherwise suppress Golgi localization. We propose that varying the expression of differentially localized isoforms provides a means to influence the spectrum of substrates encountered by USP33.

18 September 2018 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
JWJonathan Woodsmith
Jonathan Woodsmith
VCVictoria Casado-Medrano
Victoria Casado-Medrano
NBNouhad Benlasfer
Nouhad Benlasfer
RERebecca L Eccles
Rebecca L Eccles
SHSaskia Hutten
Saskia Hutten
USUlrich Stelzl
Ulrich Stelzl
Systematic analysis of human arginine methylation identifies two distinct signaling modes; either isolated modifications akin to canonical post-translational modification regulation, or clustered arrays within disordered protein sequence. Hundreds of proteins contain these methyl-arginine arrays and are more prone to accumulate mutations and more tightly expression-regulated than dispersed methylation targets. Arginines within an array in the highly methylated RNA-binding protein synaptotagmin binding cytoplasmic RNA interacting protein (SYNCRIP) were experimentally shown to function in concert, providing a tunable protein interaction interface. Quantitative immunoprecipitation assays defined two distinct cumulative binding mechanisms operating across 18 proximal arginine–glycine (RG) motifs in SYNCRIP. Functional binding to the methyltransferase PRMT1 was promoted by continual arginine stretches, whereas interaction with the methyl-binding protein SMN1 was arginine content–dependent irrespective of linear position within the unstructured region. This study highlights how highly repetitive modifiable amino acid arrays in low structural complexity regions can provide regulatory platforms, with SYNCRIP as an extreme example how arginine methylation leverages these disordered sequences to mediate cellular interactions.

5 March 2025 in Cancer Discovery
Verified
Journal Article
Closed access
RERebecca L. Eccles
Rebecca L. Eccles
GCGabriela Carreno
Gabriela Carreno
LRLorenzo de la Rica
Lorenzo de la Rica
GBGemma M. Balmer
Gemma M. Balmer
DSDavid Scott
David Scott
Summary: Here, we discuss the seven new challenges set by Cancer Grand Challenges that are currently open for creative applications. We invite the research community to assemble global, interdisciplinary teams to tackle these challenges and ultimately change the way we think about, study, prevent, and treat cancer.

7 May 2025 in Neuron
Verified
Journal Article
Closed access
GCGabriela Carreno
Gabriela Carreno
GBGemma M. Balmer
Gemma M. Balmer
RERebecca L. Eccles
Rebecca L. Eccles